NPHC · XBRL financial data

Nutra Pharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NPHC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	0	0	0	0	0	0
Cost of revenue	—	—	—	—	0	—
Cost of goods and services sold	—	0	0	0	0	0
Gross profit	0	0	0	0	0	0
Selling, general and administrative	1	2	2	1	1	—
Total operating expenses	1	2	2	1	1	2
Operating income (loss)	(1)	(2)	(2)	(1)	(1)	(1)
Interest expense	0	0	0	0	0	0
Other income (expense)	0	—	—	—	—	—
Net income (loss)	(1)	(13)	8	(1)	(1)	(2)
Earnings per share, basic USD per share	—	(0.00)	0.00	0.00	0.00	0.00
Earnings per share, diluted USD per share	—	(0.00)	0.00	0.00	0.00	0.00
Weighted average shares, basic millions of shares	—	7,233	7,503	7,608	7,674	7,779
Weighted average shares, diluted millions of shares	—	7,233	19,097	7,608	7,674	7,779

Fiscal years (NPHC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	—	0	0	0	0	0
Short-term investments	—	—	—	0	0	0
Accounts receivable	0	0	0	0	—	—
Inventory	0	0	0	0	0	0
Prepaid and other current assets	0	0	0	0	0	0
Total current assets	0	1	0	0	0	0
Property and equipment, net	0	0	0	0	0	0
Right-of-use asset	0	0	0	0	0	—
Total assets	0	1	1	1	1	1
Accounts payable	1	1	1	1	1	1
Accrued liabilities	1	1	2	2	2	2
Current portion of long-term debt	—	—	—	8	8	10
Total current liabilities	11	21	13	14	15	17
Long-term debt	—	—	—	0	0	0
Lease liability, non-current	0	—	0	0	—	—
Total liabilities	12	22	13	14	15	17
Accumulated deficit	(69)	(82)	(74)	(75)	(76)	(78)
Total stockholders' equity	(11)	(21)	(12)	(14)	(15)	(17)
Total liabilities and equity	0	1	1	1	1	1
Common shares outstanding (cover page) millions of shares	7,268	7,364	7,100	7,100	7,160	7,160

Fiscal years (NPHC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(1)	(13)	8	(1)	(1)	(2)
Stock-based compensation	0	0	0	—	—	0
Net cash from operating activities	(1)	(2)	(1)	(1)	(0)	(1)
Purchases of property and equipment	0	0	0	—	—	0
Net cash from investing activities	(0)	(0)	0	0	0	(0)
Net cash from financing activities	1	2	1	0	0	1
Net change in cash	—	0	(0)	—	0	(0)

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Nutra Pharma	not reported	0	(0.3)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
International Stem Cell	1.1	2.7	0.2*	8.0M	—	Q2 FY26 10-QJun 30, 2026
Emmaus Life Sciences	2.8	6.3	1.7*	70.2M	—	Q2 FY26 10-QJun 30, 2026
Mosaic ImmunoEngineering	0	not reported	(0)*	7.2M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Avenue Therapeutics	1.9	0	(0.5)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
China Foods Holdings	0	0	(0.1)*	20.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Hepion Pharmaceuticals	1.6	not reported	(1.4)*	90.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
America Great Health	0	0	0*	21.2B	—	Q3 FY26 10-QMar 31, 2026
Twinlab Consolidated Holdings	0	not reported	(0.9)*	259.1M	0.0 quarters	Q4 FY24 10-KDec 31, 2024

Not investment advice. Not affiliated with the U.S. SEC.